SU295559A1 - - Google Patents
Info
- Publication number
- SU295559A1 SU295559A1 SU942347A SU942347A SU295559A1 SU 295559 A1 SU295559 A1 SU 295559A1 SU 942347 A SU942347 A SU 942347A SU 942347 A SU942347 A SU 942347A SU 295559 A1 SU295559 A1 SU 295559A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- solution
- insulin
- water
- suspension
- crystalline
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003513 alkali Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Description
СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ СУСПЕНЗИИMETHOD FOR OBTAINING CRYSTALLINE SUSPENSION
,1,one
Изобретение относитс к области медицины, в частности к методам получени медицинских препаратов, и касаетс способов получени кристаллической суспензии инсулина.The invention relates to the field of medicine, in particular to methods for the preparation of medical preparations, and relates to methods for preparing a crystalline insulin suspension.
Известен способ получени кристаллической суспензии инсулина путем растворени кристаллического инсулина в воде, добавлени хлористого цинка и ацетатно-щелочного раствора и последуюа1.ей кристаллизации.A known method for producing a crystalline insulin suspension by dissolving crystalline insulin in water, adding zinc chloride and an alkaline acetate solution, and then crystallizing it.
Известный способ, предусматривающий использование специальных инокул ционных кристаллов дл затравки, приводит к значительным потер м инсулина и сравнительно сложен.A known method involving the use of special inoculation crystals for seeding leads to significant insulin losses and is relatively complex.
С целью повышени выхода и упрощени технологии производства п0 предлагаемому способу перед кристаллизацией в раствор ввод т полимер, например сополимер поливинилпнрролидоиа с поливиниловым спиртом.In order to increase the yield and simplify the production technology for the proposed method, a polymer is introduced into the solution before crystallization, for example a copolymer of polyvinyl alcohol with polyvinyl alcohol.
Пример. 450 мг перекристаллизованного инсулина раствор ют в 18,75 мл воды при рИ 2,6 и добавл ют 0,2 мл 5%-ного раствора хлористого цинка. К полученному раствору добавл ют раствор 350 мг уксуснокислого натри , 1,75 г хлористого натри и 2,5 мл Example. 450 mg of recrystallized insulin are dissolved in 18.75 ml of water at pI 2.6 and 0.2 ml of 5% zinc chloride solution is added. To the resulting solution is added a solution of 350 mg of sodium acetate, 1.75 g of sodium chloride and 2.5 ml.
ИНСУЛИНАInsulin
1 Н. едкого натра в 6,25 мл воды и раствор 450 мг сополимера поливинилнирролидона с поливиниловым спиртом в 25 мл воды. После перемешивани устанавливают значение рП раствора 5,4-5,5 и продолжают перемешивание до по влени кристаллов. Па следующий день к смеси добавл ют разбавитель, содержащий в 200 мл воды 22,5 мг едкого натра, 0,65 М.Л 5%-иого раствора хлористого цинка и 10 мл 2%-иого раствора нилогииа. После установлени рН смеси 7,2-7,3 осуществл ют перемешивание в течение 48 час.1 N. sodium hydroxide in 6.25 ml of water and a solution of 450 mg of a copolymer of polyvinylnirrolidone with polyvinyl alcohol in 25 ml of water. After stirring, set the RP value of the solution to 5.4-5.5 and continue stirring until the appearance of crystals. The next day, a diluent is added to the mixture containing 22.5 mg of sodium hydroxide, 0.65 M.L. of a 5% solution of zinc chloride and 10 ml of a 2% solution of nilogia in 200 ml of water. After adjusting the pH of the mixture to 7.2-7.3, stirring is carried out for 48 hours.
П р е дт, м е т изобретени P rde dt, mete inventions
Способ нолученн кристаллической суспензии инсулина путем растворени кристаллического инсулина в воде, добавле1И1 хлористого цинка, ацетатно-щелочиого раствора и кристаллизации , отличающийс тем, что, с целью повышени выхода и упрощегиш техиологии производства, в раствор перед кристаллизацией ввод т полимер, например сополимер иоливинилпирролидона с поливиниловым спиртом.A method for insulin crystalline suspension suspension by dissolving crystalline insulin in water, adding zinc chloride, an alkali acetate solution and crystallization, characterized in that, in order to increase the yield and simplify the manufacturing technology, a polymer, for example, a copolymer of ivivolpyrrolidone with polyvinyl, is introduced into the solution before crystallization alcohol.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU295559A1 true SU295559A1 (en) |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529589A (en) * | 1981-07-14 | 1985-07-16 | Davydov Anatoly B | Pharmaceutical composition for the treatment of diabetes mellitus |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529589A (en) * | 1981-07-14 | 1985-07-16 | Davydov Anatoly B | Pharmaceutical composition for the treatment of diabetes mellitus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112592312B (en) | Preparation method of tropicamide | |
| CN100506210C (en) | Ceftezole sodium powder injection and synthesizing method thereof | |
| CN112552196B (en) | Method for preparing lysine-piprolin | |
| CN111138457A (en) | Synthesis method of tetramisole hydrochloride | |
| SU295559A1 (en) | ||
| CN112552167B (en) | Preparation method of calcium gluconate | |
| Jackson et al. | Crystalline β-Methyl-D-ribopyranoside1 | |
| CN112279817B (en) | Preparation method of high-purity pramipexole dihydrochloride | |
| US2756226A (en) | Acid-stable penicillins | |
| CN112430633B (en) | Process for producing arginine by fermenting fed-batch culture solution | |
| JP4712166B2 (en) | Method for producing crystalline tagatose | |
| CN112279867B (en) | Preparation method of cefoperazone sodium | |
| CN112079779B (en) | Synthetic method of pentazocine | |
| CN110974832B (en) | Preparation method of cefamandole nafate for injection | |
| US2881162A (en) | Recovery process | |
| US3705150A (en) | Process for the preparation of 21-deoxy - 21-n-(n'-methylpiperazinyl)-prednisolone and salts thereof | |
| JPS604189B2 (en) | Antibacterial agents and their manufacturing methods | |
| CN107151261B (en) | Crystal form of dirithromycin compound and crystal preparation method thereof | |
| CN113620975A (en) | Synthesis method of cefpirome sulfate | |
| SU648080A3 (en) | Method of obtaining 1-tret-butylamino-3-(2,5-dichlorphenoxy)-2-propanol, its salt, racemate or optical antipod | |
| TWI701248B (en) | Glucopyranose substituted pyrazole compound, preparation method and application thereof | |
| US3888916A (en) | Amantadine salt of 16,16-dimethyl-pge' 2 | |
| CN103804204B (en) | Method for preparing key intermediate 3-amino-1-adamantanol of vildagliptin | |
| CN117447285A (en) | Preparation method of chiral impurity of beta-lactamase inhibitor intermediate | |
| WENNER | Meso-α, β-diaminosuccinic acid |